天疱疮临床研究结局测量:结局报告与定义异质性的范围综述
该范围综述系统检索2002至2023年天疱疮临床研究,纳入205项研究,提取1502个结局,归为55个结局域和11个结局领域,发现结局及测量工具存在广泛异质性,多数研究缺乏统一、患者中心且定义良好的结局,但近期有4项试验采用2008共识定义。
要点
- 天疱疮临床研究结局报告异质性大,共提取1502个结局、65种测量工具。
- 多数研究聚焦临床反应、安全监测和免疫应答,生活质量报告仅12%。
- 近期4项试验采用2008共识定义,但结局仍过严且缺乏患者中心性。
核心结论
- 过去二十年天疱疮临床研究的结局和测量工具存在广泛异质性,多数研究仍缺乏定义良好、一致且相关的结局,但近期有4项试验采用共识定义和患者中心测量工具,显示积极趋势。
研究设计与样本
- 系统检索MEDLINE、Embase、CINAHL、PsycINFO、Cochrane CENTRAL、Web of Science和试验注册库,覆盖2002年1月至2023年12月,纳入临床试验、前瞻性队列研究和系统综述,排除回顾性研究,共纳入205项研究。
主要发现
- 从205项研究中逐字提取1502个结局,归类为55个结局域和11个结局领域。
- 纳入研究主要关注临床反应(92%)、安全监测(75%)和免疫应答(61%),生活质量报告稀疏(12%)。
- 所有研究设计均观察到结局报告的异质性,临床反应领域内基于2008共识声明的定义比例随时间不一致。
- 报告了65种结局测量工具。
- 近期4项临床试验使用基于2008共识定义的主要终点。
关键数值与推荐
- 2008专家共识声明提供了标准定义,但未广泛使用;近期4项试验采用其定义,但被评价为过于严格且缺乏患者中心性。
- 天疱疮为罕见皮肤病,全球每年每10万人中诊断少于5人,中东地区发病率最高。
临床怎么用
- 临床研究中应推动使用共识定义和患者中心测量工具,以促进天疱疮研究结局的统一和可比性。
- 需通过所有利益相关方合作完善2008专家共识声明,以促进未来天疱疮结局测量的统一性和药物研发。
局限性
- 仅纳入临床试验、前瞻性队列研究和系统综述,排除回顾性研究,可能遗漏部分结局报告数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pemphigus is an autoimmune bullous disease (AIBD) and has two main subtypes, pemphigus vulgaris (PV) and pemphigus foliaceus (PF). For adequate interpretation and comparison of clinical studies in pemphigus, it is essential to have outcomes and outcome measurement instruments (OMIs) that are well-defined, uniform and relevant. OBJECTIVES: To provide a comprehensive overview of previously reported outcomes and OMIs in pemphigus clinical research over the past two decades. METHODS: A systematic literature search was performed in the databases MEDLINE, Embase, CINAHL, PsycINFO, Cochrane CENTRAL, Web of Science and trial registries covering the period between January 2002 and December 2023. Clinical trials, prospective cohort studies and systematic reviews were included. Retrospective studies were excluded. All identified outcomes and their respective OMIs were grouped into outcome domains and areas. RESULTS: From all the included studies (n = 205), a total of 1502 outcomes were extracted verbatim, categorized in 55 outcome domains and 11 outcome areas. We found a gradual increase in the number of published trials over the past two decades. The included studies mainly focused on 'clinical response' (92%), 'safety monitoring' (75%) and 'immune response' (61%). 'Quality of life' was sparsely reported (12%). Heterogeneity of reported outcomes was observed across all study designs. Within the outcome area 'clinical response', the proportion of defined outcomes based on the 2008 consensus statement has not been consistent over time. However, four recent clinical trials used primary endpoints based on the 2008 consensus definitions. Moreover, a broad spectrum of outcome measurement instruments (n = 65) was reported. CONCLUSIONS: This review showed a wide variety in reported outcomes and OMIs in pemphigus clinical research over the past two decades. Despite standardization efforts, most studies still lack well-defined, consistent and relevant outcomes and OMIs. However, a positive trend is emerging as four recent trials did use consensus-based definitions and patient-focused OMIs. Nevertheless, the outcomes are overly stringent, lack patient-centeredness, and do not include intermediate endpoints. Therefore, refinement of the 2008 expert consensus statement through collaborative efforts of all stakeholders is essential to promote uniformity in future pemphigus outcome measurement and to advance pemphigus drug development. Pemphigus is a rare skin disease. Each year, doctors worldwide diagnose fewer than 5 people per 100,000 with pemphigus. The highest rates are in the Middle East. Pemphigus causes painful blisters on the skin and/or mucous membranes (the moist lining covering the inside of various body cavities and organs). There are two main types, ‘pemphigus vulgaris’ (PV) and ‘pemphigus foliaceus’ (PF). PV is the most common type. Currently, clinical studies are evaluating new treatments for pemphigus. We aimed to give an overview of how past studies have measured the effects of these new pemphigus treatments over the past 22 years. We analysed 205 clinical studies, long-term studies and reviews that examined new treatments for PV and PF. We found big differences in how the studies measured treatment effects. Most studies focused on how well the treatment worked, potential side-effects and the immune system response. Only a few studies looked at how treatments affected patients’ quality of life. Different studies defined ‘treatment effectiveness’ differently, making it hard to compare studies. Clinical experts suggested standard definitions in 2008, but these have not been widely used. Four recent studies did follow these definitions, but they were too strict and were not patient centred. Our findings highlight the fact that we must clearly define ‘effectiveness’ in research. To do this, clinical experts, patients and regulators must work together. This would help us to compare studies, and ensure they better address the needs of people living with the condition.
引用
- Hiel MAJ, Korte EWH, Tedbirt B, et al. Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions. Br J Dermatol. 2025. PMID: 40249769. doi:10.1093/bjd/ljaf152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。